NEWS
The 2025 AD Scientific Index is here—explore updated university and researcher rankings!
New! Young University / Institution Rankings 2025
New! The 2025 Edition of the AD Scientific Index is now live!
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
"Exciting Update! The 2025 Edition of the AD Scientific Index is now live!
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Top Lists
Chetan Oturkar
Roswell Park Comprehensive Cancer Center - Buffalo / United States
Others
AD Scientific Index ID: 5658557
-
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Chetan Oturkar's MOST POPULAR ARTICLES
1-)
Mechanistic investigation of decolorization and degradation of Reactive Red 120 by Bacillus lentus BI377CC Oturkar, HN Nemade, PM Mulik, MS Patole, RR Hawaldar, KR GawaiBioresource technology 102 (2), 758-764, 20111122011
2-)
Enzyme based cleavage strategy of Bacillus lentus BI377 in response to metabolism of azoic recalcitrantCC Oturkar, MS Patole, KR Gawai, D MadamwarBioresource technology 130, 360-365, 2013492013
3-)
TP53 status as a determinant of pro-vs anti-tumorigenic effects of estrogen receptor-beta in breast cancerUK Mukhopadhyay, CC Oturkar, C Adams, N Wickramasekera, S Bansal, ...JNCI: Journal of the National Cancer Institute 111 (11), 1202-1215, 2019442019
4-)
Estrogen receptor-beta2 (ERβ2)–mutant p53–FOXM1 axis: A novel driver of proliferation, chemoresistance, and disease progression in high grade serous ovarian cancer (HGSOC)CC Oturkar, N Gandhi, P Rao, KH Eng, A Miller, PK Singh, E Zsiros, ...Cancers 14 (5), 1120, 2022142022
5-)
Therapeutic role of tamoxifen for triple-negative breast cancer: leveraging the interaction between ERβ and mutant p53L Scarpetti, CC Oturkar, D Juric, M Shellock, G Malvarosa, K Post, ...The Oncologist 28 (4), 358-363, 202372023
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept